Alemtuzumab

CHEMBL1201587 Phase 4 Aprovado Antibody

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A monoclonal antibody that depletes specific white blood cells called B and T lymphocytes, used to treat certain blood cancers and relapsing forms of multiple sclerosis. By dramatically reducing these immune cells, it can halt the autoimmune attacks that damage the protective myelin sheath around nerve fibers in MS patients.

Áreas Terapêuticas

Neurology Immunology Multiple Sclerosis

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A monoclonal antibody that depletes specific white blood cells called B and T lymphocytes, used to treat certain blood cancers and relapsing forms of multiple sclerosis. By dramatically reducing these immune cells, it can halt the autoimmune attacks that damage the protective myelin sheath around nerve fibers in MS patients.

Yes, Alemtuzumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201587. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

Procura informações acessíveis para o paciente?

Alemtuzumab no PillFYI

Dados Rápidos

Sinônimos: 2

Links Externos

ChEMBL CHEMBL1201587

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.